Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: Report of a case

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1317-1319

  Rao, Jianhua ^a   Feng, Min ^a   Qian, Xiaofeng ^a   Li, Guoqiang ^a   Wang, Xuehao ^a   Zhang, Feng ^a   Lu, Ling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic failure; Liver transplantation; Sorafenib

Indexed keywords

BILIRUBIN; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; PEPTASE; SORAFENIB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CERVICAL LYMPH NODE; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER GRAFT; LIVER GRAFT REJECTION; LYMPH NODE METASTASIS; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; THYROID PAPILLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84885702317     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13185     Document Type: Article

References (9)

1. Lam ET, Ringel MD, Kloos RT, et al.: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28(14):2323-2330.
2. Kloos RT, Ringel MD, Knopp MV, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27(10):1675-1684.
3. Zhang F, Lu L, Qian X, et al.: Liver transplantation for erythropoietic protoporphyria with hepatic failure: a case report. Transplant Proc 2008; 40(5): 1774-1776.
4. Lu L, Zhang F, Li XC, et al.: Intraoperative pulmonary hypertension occurred in an asymptomatic patient with pre-existent liver cirrhotic and portal hypertension. World J Gastroenterol 2008; 14(47):7260-7263.
5. Kane RC, Farrell AT, Saber H, et al.: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12(24):7271-7278.
6. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5):965-972.
7. Minami H, Kawada K, Ebi H, et al.: Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008; 99(7):1492-1448.
8. Herden U, Fischer L, Schäfer H: Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 2010; 90(1):98-99.
9. Kinoshita T, Inoue H, Kinouchi T, et al.: Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int J Urol 2010; 17(3):286-288.